Kiniksa Pharmaceuticals International, plc's revenue has grown 44% a year over three years, with earnings per share falling 33% a year. Revenue growth, 3-year annual rate: +44% (Drug Manufacturers - Specialty & Generic median +12%). Earnings per share, 3-year rate: −33%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 9, FY2017 to FY2025, as filed.

KNSAKiniksa Pharmaceuticals International, plc

Healthcare

$76.71+97% 1Y

$76.71

$37.0152 weeks$83.18

Is it growing?

Excellent

Growing: revenue growing +59% year on year, earnings up +2350% year on year, and operating margin widening (+12.4 points).

3 good

Revenue trend+59% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Earnings trend+2350% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction+12.4 points operating

Trailing-twelve-month operating margin, 12.0% now against -0.5% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is KNSA growing?

Kiniksa Pharmaceuticals International, plc's revenue has grown 44% a year over three years, with earnings per share falling 33% a year.

+44%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +12% · compounding fast · compounded from trailing twelve-month revenue

Earnings per share, 3-year rate: −33%
Earnings per share, 3-year rate · revenue +44% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 9
Years of annual history on file · FY2017 to FY2025, as filed

Details›